The Planned Acquisition Would Enhance the Management Team, Provide Capital and Bring Additional Oncology Assets to Immune’s Pipeline   ORLANDO, Fla., December 16th, 2019  -- -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a privately held development-stage oncology therapeutics company, today announced that Immune will acquire Aletheia in an all-stock transaction.  Pursuant to completion of a definitive agreement,...

read more